Virtus Fund Advisers, LLC Jounce Therapeutics, Inc. Transaction History

Virtus Fund Advisers, LLC

  • $20.2 Million
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
SELL
$2.73 - $4.92 $73,568 - $132,584
-26,948 Closed
0 $0
Q4 2017

Feb 09, 2018
BUY
$12.52 - $17.82 $337,388 - $480,213
26,948
26,948 $344,000

Others Institutions Holding JNCE

# of Institutions
4
Shares Held
720K
Call Options Held
0
Put Options Held
0
View Full List

About Jounce Therapeutics, Inc.

JNCE Quotes by TradingView
  • Ticker JNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,694,200
  • Description
  • Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...
More about JNCE
Track This Portfolio

Track Virtus Fund Advisers, LLC Portfolio

Follow Virtus Fund Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus Fund Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus Fund Advisers, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email